Author:
McCafferty Emma H.,Scott Lesley J.
Publisher
Springer Science and Business Media LLC
Reference61 articles.
1. Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416–27.
2. Amicus Therapeutics. Galafold™ (migalastat) capsules, for oral use: US prescribing information. 2018.
https://www.fda.gov/
. Accessed 18 Oct 2018.
3. European Medicines Agency. Migalastat (Galafold): EU summary of product characteristics. 2018.
https://www.ema.europa.eu/
. Accessed 18 Oct 2018.
4. Brady RO, Gal AE, Bradley RM, et al. Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficiency. N Engl J Med. 1967;276(21):1163–7.
5. National Institute for Health and Care Excellence. Migalastat for treating Fabry disease. 2017.
https://www.nice.org.uk/guidance/hst4
. Accessed 26 Oct 2018.
Cited by
115 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献